Abstract
We documented the prevalence of retinopathy of prematurity (ROP) in a group of 46 infants suffering from a moderate or severe respiratory distress syndrome and treated with surfactant replacement therapy (SRT) and 61 controls admitted in the year prior to the institution of SRT. Mortality in the treatment group was lower than in the control group (15.5% versus 23.8;P=0.29). The ROP prevalence in the treatment group was 47.8% and in the control group was 47.8% and in the control group 27.9%. To analyse the contribution of SRT alone to the prevalence of ROP, multivariate analysis using logistic regression technique was used. The odds ratio for SRT was 5.2 with a 95% confidence interval of 1.3–20.7,P=0.02. The prevalence of severe ROP in the surfactant treated group was not increased compared to the control group. From our data we conclude that SRT increases the risk of developing ROP but is not associated with more severe forms of ROP.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- NICU :
-
neonatal intensive care unit
- RDS :
-
respiratory distress syndrome
- ROP :
-
retinopathy of prematurity
- SRT :
-
surfactant replacement therapy
References
Avery GB, Glass P (1988) Retinopathy of prematurity; what causes it? Clin Perinatol 15(4):917–928
Ben Sira I, Nissenkorn I, Kremer I (1988) Retinopathy of prematurity. Surv Ophthalmol 33(1):1–17
Bossi E, Koerner F, Flury B, Zulauf M (1984) Retinopathy of prematurity: a risk factor analysis with univariate and multivariate statistics. Helv Paediatr Acta 39:307–317
Collaborative European Multicenter Study Group (1988) Surfactant replacement therapy for severe neontal respiratory distress syndrome: an international randomized clinical trial. Pediatrics 82:683–691
Committee for the Classification of Retinopathy of Prematurity (1987) An international classification of retinopathy of prematurity II. The classification of retinal detachment. Arch Ophthalmol 105:906–912
Corbet A, Bucciavelli R, Goldman S, Mammel M, Wold D, Long W, American Exosurf Pediatric Study Group 1 (1991) Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. J Pediatr 118:277–284
Dunn MS, Shennan AT, Zayack D, Possmayer F (1991) Bovine Surfactant Replacement therapy in neonates of less than 30 weeks gestational age: a randomized controlled trial of prophylaxis versus treatment. Pediatrics 87: 377–386
Fielder A, Shaw D, Robinson J, Ng Y (1992) Natural history of retinopathy of prematurity: a prospective study. Eye 6:233–242
Fujiwara T, Koniskhi M, Chida S, Okuyama K, Ogawa Y, Takeuchi Y, Nishida H, Kito H, Fujimura M, Nakamura H, Hashimoto T (1990) Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome: final analysis of a multicenter, double-blind, randomized trial and comparison with similar trials. Pediatrics 86:753–764
Garner A (1990) The role of hyperoxia in the aetiology of retinopathy of prematurity. Doc Ophthalmol 74:187–193
Giedion A, Haefliger H, Dangel P (1973) Acute pulmonary X-ray changes in hyaline membrane disease treated with artificial ventilation and positive and expiratory pressure. Pediatr Radiol 1:145–152
Hennes HM, Lee MB, Rimm AA, Shapiro DL (1991) Surfactant replacement therapy in respiratory distress syndrome. Meta-analysis of clinical trials of single-dose surfactant extracts. Am J Dis Child 145:102–104
Johnson L, Schaffer D, Quinn G, Goldstein D, Mathis MJ, Otis C, Boggs TR Jr (1982) Vitamin E supplementation and the retinopathy of prematurity. Ann NY Acad Sci 393:473–494
Kretzer FL, Hittner HM, Johnson AJ, Mehta RS, Godio LB (1982) Vitamin E and retrolental fibroplasia: ultrastructural support of clinical efficacy. Ann NY Acad Sci 393:145–166
Kretzer FL, Mehta RS, Johnson AT, Hunter DG, Brown ES, Hittner HM (1984) Vitamin E protection against retinopathy of prematurity through action on spindle cells. Nature 309:793–795
Prendiville A, Schulenburg W (1982) Clinical factors associated with retinopathy of prematurity. Arch Dis Child 57:247–252
Rankin SJA, Tubman TRJ, Halliday HL, Johnston SS (1992) Retinopathy of prematurity in surfactant treated infants. Br J Ophthalmol 76:202–204
Repka MX, Hudak ML, Parsa CF, Tielsch JM (1991) Calf lung surfactant extract prophylaxis and retinopathy of prematurity. Ophthalmology 99: 531–536
Seiberth V, Freiwald R, Knorz MC (1991) Risk factors in retinopathy of prematurity: a multivariate statistical analysis. Invest Ophthalmol Vis Sci 33:2343–2344
Sotolongo L, Ferguson O, Yedavally S, Iverson D (1992) A comparison of the incidence and severity of retinopathy of prematurity between age and weight matched infants treated with and without surfactant. Invest Ophthalmol Vis Sci 33:1967–77
Speer CP, Robertson B, Curstedt T, Halliday HL, Compagnone D, Gefeller O, et al (1992) Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics 89:13–20
Tan KEWP, Cats BP (1989) Timely incidence of retinopathy of prematurity (ROP) and its consequences for the screening strategy. Am J Perinatol 6: 337–340
Tubman TRJ, Rankin SJ, Halliday HL, Johnston SS (1992) Surfactant replacement therapy and the prevalence of acute retinopathy of prematurity. Biol Neonate 61 [Suppl 1]:54–58
Van de Bor M, Ma EJ, Walther FJ (1991) Cerebral blood flow velocity after surfactant instillation in preterm infants. J Pediatr 118:285–287
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Termote, J.U.M., Schalij-Delfos, N.E., Wittebol-Post, D. et al. Surfactant replacement therapy: A new risk factor in developing retinopathy of prematurity?. Eur J Pediatr 153, 113–116 (1994). https://doi.org/10.1007/BF01959221
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01959221